ClinicalTrials.gg
CompletedNCT04001348Updated Jun 28, 2019

Characteristics of Different Types of Safety Lancets on Blood Volume and Perceived Pain in Male and Female Volunteers

An interventional study of Acti-Lance Lite and Acti-Lance Universal in Healthy, sponsored by HTL-Strefa S.A.. Completed at 1 site in Poland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-28.

Sponsored by HTL-Strefa S.A. · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 6 years after the study started (first participant enrolled Jun 2013, registered Jun 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study was a randomized, single blind, uni-center pivotal study in male and female healthy volunteers, to determine capillary blood volume and pain perception obtained in a process of puncturing with different safety lancets.

A group of one hundred (100) healthy Caucasian male and female Subjects (aged > 18 to \< 65 years old was randomized ) who were in good physical and mental condition. The Subjects had 4 (four) fingers (two fingers from each hand) lanced each with a different type of safety lancet. Overall, 4 (four) different safety lancets were investigated per each Subject.

Overall, 16 (sixteen) different safety lancets (4 different safety lancets per one Subject) were investigated, the capillary blood volume and pain were measured.

02

Conditions studied

  • Healthy

Browse trials for

Keywords

  • safety lancets
  • lancet
  • capillary blood
  • capillary blood sampling
  • blood volume
  • pain
03

In context

Pain

10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.

This study's enrollment of 100 is above the median of 66 across 8,493 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

HTL-Strefa S.A. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to sign the .
  • Male and female volunteers.
  • Age between 18 and 65 inclusive.
  • Able to communicate well with the Investigator and comply with the requirements of the study.
  • Volunteers who are in good physical and mental health.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding (self-reported).
  • Confirmed or suspected malignant cancer History of poor blood circulation.
  • Any skin condition on his or her fingers that prevents blood sampling.
  • Anxiety with needles or finger pricks.
  • Clotting disorders (including bleeding) in medical history.
  • Neuropathy or other condition affecting sensation in the hands.
  • History of blood borne infection (e.g., , or C, syphilis, malaria, babesiosis, brucellosis, leptospirosis, arboviral infections, relapsing fever, T lymphotropic virus Type 1, Creutzfeldt-Jakob disease).
  • Currently participating in another study.
  • History of drug or alcohol abuse within the 12 months prior to screening or evidence of such abuse.
  • Intake of alcohol within 48 hours prior to the start of the study (self-reporting).
  • Donation or loss of 400 mL or more of blood within 4 weeks prior to the start of the study.
  • Any other condition that in the Investigator opinion may negatively influence Subject's participation in the study.
  • Intake of medicines that affect blood coagulability (including anticoagulants such as vitamin K, antivirals and anticoagulants such as heparin, aspirin, thrombin inhibitors, vitamin K antagonists).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    HTL-STREFA S.A.safety lancet type 610

    Device: Acti-Lance Lite · Device: Acti-Lance Universal · Device: Acti-Lance Special

  • Experimental
    HTL-STREFA S.A.safety lancet type 553-556

    Device: Medlance Plus Super Lite · Device: Medlance Plus Lite · Device: Medlance Plus Universal · Device: Medlance Plus Extra · Device: Medlance Plus Special

  • Experimental
    HTL-STREFA S.A.safety lancet type 430

    Device: Prolance Micro Flow · Device: Prolance Low Flow · Device: Prolance Normal Flow · Device: Prolance High Flow · Device: Prolance Max Flow · Device: Prolance Pediatric

  • Experimental
    HTL-STREFA S.A.safety lancet type 520

    Device: MediSafe Solo 29 Gauge · Device: MediSafe Solo 23 Gauge

Interventions

  • DeviceActi-Lance Lite

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 610

  • DeviceActi-Lance Universal

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 610

  • DeviceActi-Lance Special

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 610

  • DeviceMedlance Plus Super Lite

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 553-556

  • DeviceMedlance Plus Lite

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 553-556

  • DeviceMedlance Plus Universal

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 553-556

  • DeviceMedlance Plus Extra

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 553-556

  • DeviceMedlance Plus Special

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 553-556

  • DeviceProlance Micro Flow

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 430

  • DeviceProlance Low Flow

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 430

  • DeviceProlance Normal Flow

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 430

  • DeviceProlance High Flow

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 430

  • DeviceProlance Max Flow

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 430

  • DeviceProlance Pediatric

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 430

  • DeviceMediSafe Solo 29 Gauge

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 520

  • DeviceMediSafe Solo 23 Gauge

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 520

06

What researchers measure

Primary outcomes

  1. Volume (microliters) of blood in the capillary tube

    The amount of capillary blood volume collected after a single lancing of the fingertip.

    Time frame: The blood from the puncture site was collected to the capillaries by pressing during 2 minutes

Secondary outcomes

  1. Pain perception: VAS

    The intensity of pain perceived by the patient was assessed with the use of the numeric Visual Analog Scale (VAS). The Subject marked on the scale the number from 0 ("no pain") to 10 ("worst imaginable pain") that represented their perception of pain. A higher score indicated greater pain intensity.

    Time frame: 5 minutes after lancing

07

Study locations

1 site
  • Monipol Clinical Pharmacology Research Centre
    Cracovia, Malopolskie 30-969, Poland
08

References and documents

Publications

  • Serafin A, Malinowski M, Prazmowska-Wilanowska A. Blood volume and pain perception during finger prick capillary blood sampling: are all safety lancets equal? Postgrad Med. 2020 Apr;132(3):288-295. doi: 10.1080/00325481.2020.1717160. Epub 2020 Feb 6. PubMed 32027205 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Jul 2013, 1 month.

Of 99 industry-sponsored interventional studies with no phase under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 1 month is below that.

Counting every sponsor, half of 3,830 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2019
First posted
Jun 28, 2019
StartActual
Jun 2013
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Last update
Jun 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04001348
Lead sponsor
HTL-Strefa S.A.
Responsible party
Sponsor
First posted
Jun 28, 2019
Start date
Jun 2013
Primary completion
Jul 2013
Completion
Jul 2013
Last update
Jun 28, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion